CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial Ticagrelor with or without Aspirin in High-Risk Patients after PCI Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling

Review Article2020 Jul 1;9(7):E2064.

JOURNAL:J Clin Med . Article Link

Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective

G Tersalvi, L Biasco, GM Cioffi et al. Keywords: P2Y12 inhibition; acute coronary syndrome; bleeding; clopidogrel; dual antiplatelet therapy; high bleeding risk; prasugrel; tailored therapy; ticagrelor

Full Text PDF